BPC-157 Side Effects: What Is Known in People, and What Nobody Has Measured

BPC-157’s side effects in people are mostly unknown, because almost nobody has studied them. Five small human studies, none dosing for longer than two weeks, reported no serious problems. In the one study that listed common complaints, headache and flatulence led, with no obvious difference from placebo.^[1] FDA’s adverse-event database held three reports through December 2025: injection-site redness and swelling, shortness of breath that ended in an emergency room visit, and skin and gum darkening after a research-labeled BPC-157 and TB-500 blend.^[1] None of those has been proven to come from BPC-157. The larger risks are the ones no one has measured: immune reactions to an injected peptide, impurities in the vial, and the open question of whether a drug that grows blood vessels could also feed a tumor.

What the human studies reported

When FDA’s reviewers searched PubMed and Embase for its May 2026 briefing document, they found five clinical studies in which people were given BPC-157.^[1] Two exist only as conference abstracts. The other three share a first author, come from Florida clinics, and appeared in one alternative-medicine journal.^[3][4][5] Together they gave BPC-157 to about 80 people, and none dosed anyone for longer than two weeks.

FDA’s summary of this record is careful. No serious adverse events appear to have been reported, but the studies “were of short duration, had small sample sizes, evaluated doses that were likely exploratory in nature, and the authors provided limited information on safety data.”^[1] Safety monitoring was unclear in most of them. In the enema studies, BPC-157 was not detected in the blood, so those volunteers may have absorbed little of it.^[1] No published study has measured what happens in the body after the routes people actually use: under the skin, by mouth, in the nose or on the skin.^[1]

Independent reviewers read the same papers the same way. A 2026 systematic review counted three eligible studies with 30 participants in total, judged all three to be of poor quality, and rated the certainty of the evidence very low. Its authors concluded that BPC-157 should not be used outside ethically approved clinical trials.^[6] A 2025 review from the University of Utah noted that no adverse effects were reported but that rigorous, large-scale trials are lacking.^[15] A study too small to see a side effect cannot show that the side effect is absent. With 12 or 17 people and a single exposure, a reaction that strikes 1 user in 100 would most likely never appear. The dose ranges in these studies are covered in BPC-157 dosage in the studies.

The three reports in FDA’s adverse-event database

FDA searched its Adverse Event Reporting System (FAERS) for BPC-157 through December 4, 2025 and found three reports, all involving injected products.^[1]

• Redness and swelling at the injection site for nine days, in a 55-year-old woman using a compounded BPC-157 injection. She was also injecting compounded thymosin, so FDA could not separate the two.^[1]
• Shortness of breath leading to an emergency room visit, in a 28-year-old man using compounded BPC-157 acetate under the skin for an injury. The report gave no timing, duration or other medicines.^[1]
• Darkening of the skin and gums, in a 40-year-old woman injecting a BPC-157 and TB-500 blend labeled “research purposes only” twice a day. The reaction came back identically when she restarted the product and stopped when she quit. FDA judged the product a likely cause but could not say which of the two peptides was responsible.^[1]

A separate search of FDA’s food and supplement complaint system turned up three more cases, each muddied by multi-ingredient supplements and missing details. FDA found no published case reports at all.^[1] Three reports should not be read as three problems in a large user base. FAERS depends on someone choosing to file, and FDA’s own footnote says that 503A compounding pharmacies “generally do not report adverse events to FDA.”^[1] Most BPC-157 has been sold as a research chemical, outside any reporting system. The count reflects how little was reported and says almost nothing about how often harm happens.

What the animal toxicology flags

The one formal toxicology package for BPC-157 comes from a 2020 study in mice, rats, rabbits and dogs. Its authors reported that the peptide was well tolerated, caused no genetic damage or harm to fetuses in pregnant rats, and produced only mild irritation where it was injected. In dogs, creatinine fell at the highest dose and recovered after two weeks off.^[7]

FDA’s reviewers read the same data less reassuringly. In the 28-day studies, given into muscle, they found what they called “clinically relevant safety signals”: changes in a clotting test (aPTT shortened in rats and lengthened in dogs) and liver-associated signals, including higher ALT, glucose and triglycerides.^[1] They also pointed out what is missing. No study ran longer than 28 days, so nobody knows whether new problems appear with longer use. No study tested whether BPC-157 causes cancer. No toxicology study used the oral, under-the-skin, nasal or skin routes, and because absorption by those routes is unknown, the safe levels found in muscle studies cannot be carried over to them.^[1] In animals the peptide disappears from the blood within minutes, with a half-life of 5.3 minutes in dogs and 15.2 minutes in rats.^[1]

The cancer question: what the papers actually argue

The tumor worry repeated across the internet comes from BPC-157’s best-studied effect. In lab and rat experiments it promotes angiogenesis, the growth of new blood vessels, partly by raising and activating VEGFR2, a receptor for one of the body’s main blood-vessel growth signals.^[8] New vessels help a torn tendon heal. Tumors also need them to grow.

A 2025 review by researchers in Warsaw and Gdansk set out that argument. They noted that VEGF receptors are expressed in about half of the human cancers studied, and that in mice with implanted cancer cells, BPC-157 did not meaningfully shrink the tumors. They concluded that the peptide “may not be the right choice, especially in situations where we are not aware of the presence of cancer cells in our body.”^[9] The University of Zagreb group that produced most of the BPC-157 research replied in print, calling the tumor link speculation and arguing that BPC-157 regulates blood-vessel growth and has anti-tumor effects in animal and cell studies.^[10] A 2026 review on unregulated “biohacking” drugs lists pathological angiogenesis and carcinogenesis among the possible risks of peptides such as BPC-157.^[11]

Neither side has human data. The concern is a reasoned inference from how the peptide works, and the rebuttal comes from the group with the most invested in the molecule. What would settle it is a carcinogenicity study, and FDA found none.^[1] For someone with a current cancer, a past cancer or a strong family history, the question is open and should be raised with a doctor before starting.

“There is insufficient clinical safety information to characterize the safety profile of BPC-157 (free base) and BPC-157 acetate.”^[1]

— FDA briefing document on BPC-157, May 2026

Immune reactions and impurities: CDER’s concern

The risk FDA’s drug center (CDER) wrote about most is immunogenicity: the body making antibodies against the peptide. FDA’s review says that, as a 15-amino-acid peptide given by injection or nasal spray, BPC-157 “may pose a significant risk for immunogenicity, potentially amplified by aggregation as well as potential peptide-related impurities.”^[1] The outcomes it describes range from antibodies with no symptoms to “life-threatening and catastrophic reactions,” and they are hard to predict. Antibodies can also neutralize a drug or, in principle, a related protein the body makes itself.^[1] FDA found no study that formally looked for antibodies to BPC-157.^[1]

Route matters. FDA rates the inherent immune risk of BPC-157 taken by mouth as “likely to be low” and that of injected and nasal forms as higher.^[1] Impurities matter too. Making a peptide one amino acid at a time leaves behind shortened and altered chains that look much like the real molecule and are hard to detect without sophisticated testing. Peptides can also clump into aggregates, which raise immune risk. FDA found that most certificates of analysis for BPC-157 reported purity alone, with no impurity results.^[1] Our guide to reading a peptide certificate of analysis shows what a complete one contains.

Research-use-only vials: the risk HHS named

On October 28, 2026, HHS said it would stop taking enforcement action against 503A pharmacies that compound BPC-157 under set conditions. Its stated reason was safety. The policy aims to discourage “the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients.”^[2] A 2026 orthopedic review lists the problems with those products: uncertain identity, purity, concentration, sterility and consistency.^[12] The one FAERS case with a reaction that returned on rechallenge involved a research-labeled blend.^[1] The differences between the two supply routes are covered in research-use-only vs. compounded peptides.

What the October 2026 policy changes for safety

The policy does not approve BPC-157, and a compounded drug is not FDA-approved; FDA does not review its safety before it is sold.^[2] What it does is set conditions aimed at the gaps FDA identified. HHS said its BPC-157 decision rested partly on a lot-specific certificate from an FDA-registered facility reporting the identity, impurity, endotoxin, microbial and residual-solvent results CDER had found missing.^[2]

Each row is from the policy text.^[2] The single-ingredient rule means a pharmacy may not compound the BPC-157 and TB-500 blends common on research-chemical sites; peptide blends and stacks explains why. Oral capsules have their own hurdle, covered in oral BPC-157 capsules. HHS also reserved the right to revisit the policy if “a safety signal or product quality issue arises.”^[2] The reporting condition is meant to produce exactly that kind of signal. Our overview of the 2026 HHS peptide policy covers all six peptides.

What nobody has measured

• Use beyond two weeks. No human study has dosed anyone for longer than two weeks, so nothing is known about months of use.^[1]
• Absorption by the common routes. There are no human pharmacokinetic data after oral, under-the-skin, nasal or skin use.^[1] A 2015 oral safety trial in healthy volunteers (NCT02637284) was registered with an estimated 42 people. Its status is unknown, and no results have been posted or published.^[13]
• Antibodies. No study has tested whether users develop antibodies to BPC-157.^[1]
• Cancer risk. No carcinogenicity study exists in animals or people.^[1]
• Pregnancy and breastfeeding. The only reproductive data come from rats dosed into muscle partway through pregnancy; no study covered fertility or development after birth.^[1]
• Long-term safety in general. Reviewers in orthopedics put it plainly: validated dosing, pharmacokinetic and long-term safety data are lacking.^[12]

If you take BPC-157, or are thinking about it

• Tell the doctor who treats you, especially if you have or have had cancer, take a blood thinner, or have liver disease, given the clotting and liver signals in the animal studies.^[1]
• Report problems to MedWatch. Patients can file directly with FDA, whatever the product’s source.^[14] Reports are how a safety signal gets noticed. Our peptide monitoring guide explains how to file one.
• Avoid blends. If something goes wrong with a two-peptide product, nobody can tell which peptide caused it.^[1]
• Get urgent care for trouble breathing, swelling of the face or throat, or a spreading rash after a dose. Those are signs of a serious allergic reaction from any injected product.

If you are on a GLP-1 and considering adding peptides, peptides alongside a GLP-1 covers what changes. For pharmacies and prescribers working under the new policy, see where to get BPC-157.

Common questions